GAROFALO ELIZABETH A. 4

What Happened

• Elizabeth A. Garofalo, a director of Xenon Pharmaceuticals (XENE), had 2,645 derivative units converted/exercised into common shares on June 1, 2026 (reported as code M). The filing also shows a corresponding disposition entry for 2,645 derivative units at $0.00 on the same date.
• On June 3, 2026 she was granted two RSU awards totaling 12,100 RSUs (10,507 and 1,593 RSUs), reported at $0.00 consideration. These new RSUs are awards/contingent rights to receive common shares in the future.

Key Details

• Transaction dates & prices:
  • 2026-06-01: Exercise/conversion (code M) — 2,645 shares; price reported $0.00.
  • 2026-06-01: Disposition line (code M) — 2,645 shares; price $0.00 (filing provides no further explanation for this line beyond the vesting/settlement entries).
  • 2026-06-03: Grants/awards (code A) — 10,507 RSUs and 1,593 RSUs; price $0.00.
• Shares owned after transaction: Not specified in the information provided in this summary.
• Footnotes:
  • F1: The 2,645 shares arose from RSUs granted June 5, 2025 that vested 100% on June 1, 2026.
  • F2/F3: The June 3 RSU awards vest 100% on the earlier of June 1, 2027 or the day before the 2027 annual meeting; each RSU represents the right to one common share.
• Timeliness: Reported period 2026-06-01 and filed 2026-06-03 — appears to be timely.

Context

• These entries reflect compensation-related vesting and new RSU grants (not open-market purchases or sales). RSU vesting and grant activity is commonly part of routine executive/director compensation and does not necessarily signal a personal buy/sell decision.
• The filing uses code M for conversion/exercise of derivatives (here, conversion/settlement of vested RSUs) and code A for awards/grants. The record includes a disposition line tied to the June 1 activity; the filing does not explain any tax withholding or share-retention details.